FY26 Annual Report filed with 47th AGM notice; revenue up 33% to ₹22,756 mn

Board & Shareholder Meetings View source PDF

ASTRAZEN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+0.6%1-day move

₹8022.50

prior close

—

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

————+0.6-0.1-1.8-0.1+1.1—————

Up moveDown movePending

AI summary

AstraZeneca Pharma India filed FY26 Annual Report with 47th AGM notice. AGM on Aug 10, 2026 at 3 pm via video conferencing. Total revenue grew 33% year on year to ₹22,756 million. Oncology revenue ₹16,101 million (up 44%), Biopharmaceuticals ₹5,243 million (up 7.2%), Rare Disease ₹215 million (up 7x). 11 regulatory approvals secured. Bengaluru manufacturing operations exited during the year.

Likely market impact

Confirms strong FY26 results with 33% revenue growth. AGM on Aug 10 to address routine shareholder business; no major surprises expected.